Advertisement
GSK vs JNJ
Which Stock Would AI Choose? GlaxoSmithKline (GSK) vs. Johnson & Johnson (JNJ) Stock Comparison
Key Takeaways
- GSK has shown stronger recent core sales growth driven by specialty medicines and vaccines, while JNJ maintains broader stability across pharmaceuticals and MedTech.
- JNJ trades at a higher valuation with a market capitalization exceeding $640 billion compared to GSK’s approximately $96 billion in ADR terms.
- Both companies have advanced oncology pipelines, with GSK pursuing acquisitions such as Nuvalent and JNJ reporting extended survival data for RYBREVANT.
- JNJ exhibits lower volatility with a beta of 0.23 versus 0.29 for GSK, supporting more consistent price behavior in recent market activity.
- Dividend focus remains key for both, with GSK reaffirming its 2026 payout and JNJ extending its long streak of increases.
- Recent weeks highlight GSK’s R&D acceleration plans alongside JNJ’s portfolio optimization efforts, including potential divestitures.
Introduction
GlaxoSmithKline (GSK) and Johnson & Johnson (JNJ) represent two established players in the global healthcare sector, offering investors exposure to pharmaceuticals, vaccines, and medical technologies. This comparison examines their relative performance, business drivers, and market positioning in the current environment. Institutional and retail investors seeking diversified healthcare exposure or evaluating large-cap defensive names may find the analysis useful for assessing trade-offs between growth momentum and stability.
GSK Overview and Recent Performance
GlaxoSmithKline (GSK) operates as a global biopharmaceutical company focused on specialty medicines, vaccines, and general medicines. In recent weeks, the stock has experienced modest fluctuations amid broader market activity, with the ADR trading near $48.13. Second-quarter results demonstrated 5% sales growth at constant exchange rates, led by specialty medicines and vaccines, alongside reaffirmed full-year guidance for turnover growth of 3% to 5%. Key influences on sentiment include ongoing R&D acceleration with plans for more than 20 phase III trial starts in 2026, cost-restructuring initiatives, and pipeline advancements such as oncology licensing deals and positive trial data for assets like Jideytro. Recent market activity has also featured discussions around potential acquisitions to bolster the oncology portfolio.
JNJ Overview and Recent Performance
Johnson & Johnson (JNJ) is a diversified healthcare company with leading positions in pharmaceuticals and MedTech. The stock has traded near $265.58 in recent sessions, reflecting relative stability within the sector. Recent performance has been supported by positive clinical updates, including extended overall survival data for RYBREVANT in lung cancer and CE marking for new contact lens products. Portfolio adjustments, such as potential divestiture of the orthopedics unit, have drawn attention alongside continued investment in U.S. manufacturing and pipeline expansion. Broader market activity shows the company maintaining guidance momentum from earlier quarters, with emphasis on innovation in oncology and immunology contributing to steady investor interest.
Trending AI Robots
Tickeron’s Trending AI Robots page curates high-performing automated trading strategies from hundreds of AI trading bots that cover thousands of tickers. Only those demonstrating strong alignment with prevailing market conditions, consistent risk-adjusted returns, and suitable trading styles earn placement in this section. Available bots span diverse strategies, timeframes, and performance statistics, with many showing win rates in the 55-75% range and varying drawdown profiles depending on the underlying assets. Traders can review detailed metrics for each robot before deployment. Explore the full selection on the Trending AI Robots page to identify options matching specific objectives.
Head-to-Head Comparison
GlaxoSmithKline (GSK) emphasizes specialty medicines and vaccines with a more concentrated growth profile tied to pipeline execution and recent acquisitions, whereas Johnson & Johnson (JNJ) benefits from diversified revenue across pharmaceuticals and MedTech, supporting greater resilience. Recent momentum favors GSK on core earnings beats and R&D expansion, while JNJ demonstrates stronger trend consistency and lower beta. Risk factors include patent exposure for GSK’s HIV franchise versus litigation and regulatory considerations for JNJ. Sector exposure overlaps in oncology but differs in MedTech breadth for JNJ. Market sentiment reflects GSK’s higher growth orientation balanced against JNJ’s scale and dividend reliability.
Tickeron AI Verdict
Based on observable factors such as trend consistency, lower volatility, and established market positioning, Tickeron’s AI would currently assign a higher probabilistic preference to JNJ for strategies prioritizing stability over near-term catalysts. GSK shows competitive positioning in pipeline-driven growth but with greater variability in recent price behavior.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GSK is a Hold and JNJ is a Buy.
GSK | JNJ | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 72 | 72 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 5 Undervalued | 12 Undervalued | |
PROFIT vs RISK RATING 1..100 | 46 | 4 | |
SMR RATING 1..100 | 34 | 37 | |
PRICE GROWTH RATING 1..100 | 55 | 50 | |
P/E GROWTH RATING 1..100 | 53 | 10 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GSK's Valuation (5) in the Pharmaceuticals Major industry is in the same range as JNJ (12). This means that GSK’s stock grew similarly to JNJ’s over the last 12 months.
JNJ's Profit vs Risk Rating (4) in the Pharmaceuticals Major industry is somewhat better than the same rating for GSK (46). This means that JNJ’s stock grew somewhat faster than GSK’s over the last 12 months.
GSK's SMR Rating (34) in the Pharmaceuticals Major industry is in the same range as JNJ (37). This means that GSK’s stock grew similarly to JNJ’s over the last 12 months.
JNJ's Price Growth Rating (50) in the Pharmaceuticals Major industry is in the same range as GSK (55). This means that JNJ’s stock grew similarly to GSK’s over the last 12 months.
JNJ's P/E Growth Rating (10) in the Pharmaceuticals Major industry is somewhat better than the same rating for GSK (53). This means that JNJ’s stock grew somewhat faster than GSK’s over the last 12 months.
| GSK | JNJ | |
|---|---|---|
| RSI ODDS (%) | N/A | 6 days ago 29% |
| Stochastic ODDS (%) | 3 days ago 47% | 3 days ago 49% |
| Momentum ODDS (%) | 3 days ago 67% | 3 days ago 45% |
| MACD ODDS (%) | 3 days ago 71% | 3 days ago 39% |
| TrendWeek ODDS (%) | 3 days ago 54% | 3 days ago 47% |
| TrendMonth ODDS (%) | 3 days ago 52% | 3 days ago 44% |
| Advances ODDS (%) | 11 days ago 64% | 3 days ago 47% |
| Declines ODDS (%) | 3 days ago 54% | 5 days ago 40% |
| BollingerBands ODDS (%) | 3 days ago 75% | 3 days ago 45% |
| Aroon ODDS (%) | 3 days ago 41% | 3 days ago 46% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GSK’s FA Score shows that 1 FA rating(s) are green while JNJ’s FA Score has 3 green FA rating(s).
- GSK’s FA Score: 1 green, 4 red.
- JNJ’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GSK’s TA Score shows that 4 TA indicator(s) are bullish while JNJ’s TA Score has 4 bullish TA indicator(s).
- GSK’s TA Score: 4 bullish, 6 bearish.
- JNJ’s TA Score: 4 bullish, 4 bearish.
Price Growth
GSK (@Pharmaceuticals: Major) experienced а -1.95% price change this week, while JNJ (@Pharmaceuticals: Major) price change was +0.46% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.05%. For the same industry, the average monthly price growth was -5.35%, and the average quarterly price growth was +17.52%.
Reported Earning Dates
GSK is expected to report earnings on Oct 28, 2026.
JNJ is expected to report earnings on Oct 13, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+0.05% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
GSK and
Correlation & Price change
A.I.dvisor indicates that over the last year, GSK has been loosely correlated with NVS. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if GSK jumps, then NVS could also see price increases.